These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 18322395)

  • 1. The role of alpha-synuclein in neurodegenerative diseases: a potential target for new treatment strategies?
    Windisch M; Wolf H; Hutter-Paier B; Wronski R
    Neurodegener Dis; 2008; 5(3-4):218-21. PubMed ID: 18322395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?
    Windisch M; Wolf HJ; Hutter-Paier B; Wronski R
    Curr Alzheimer Res; 2007 Dec; 4(5):556-61. PubMed ID: 18220522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
    Gallardo G; Schlüter OM; Südhof TC
    Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional protein kinase arrays reveal inhibition of p-21-activated kinase 4 by alpha-synuclein oligomers.
    Danzer KM; Schnack C; Sutcliffe A; Hengerer B; Gillardon F
    J Neurochem; 2007 Dec; 103(6):2401-7. PubMed ID: 17883396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?
    Windisch M; Hutter-Paier B; Schreiner E; Wronski R
    J Mol Neurosci; 2004; 24(1):155-65. PubMed ID: 15314265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic animal models of neurodegenerative diseases and their application to treatment development.
    Rockenstein E; Crews L; Masliah E
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1093-102. PubMed ID: 17869376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?
    Windisch M; Wolf HJ; Hutter-Paier B; Hofmeister A; Wronski R
    Curr Alzheimer Res; 2007 Sep; 4(4):446-57. PubMed ID: 17908049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells.
    Kazmierczak A; Strosznajder JB; Adamczyk A
    Neurochem Int; 2008 Dec; 53(6-8):263-9. PubMed ID: 18804502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
    Fodero-Tavoletti MT; Mulligan RS; Okamura N; Furumoto S; Rowe CC; Kudo Y; Masters CL; Cappai R; Yanai K; Villemagne VL
    Eur J Pharmacol; 2009 Sep; 617(1-3):54-8. PubMed ID: 19576880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. alpha-Synucleinopathy models and human neuropathology: similarities and differences.
    Kahle PJ
    Acta Neuropathol; 2008 Jan; 115(1):87-95. PubMed ID: 17932682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease?
    Armstrong RA; Lantos PL; Cairns NJ
    Neuropathology; 2008 Aug; 28(4):351-65. PubMed ID: 18433435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metals ions and neurodegeneration.
    Molina-Holgado F; Hider RC; Gaeta A; Williams R; Francis P
    Biometals; 2007 Jun; 20(3-4):639-54. PubMed ID: 17294125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain tissue microarrays in neurodegenerative diseases: validation of methodology and immunohistochemical study of growth-associated protein-43 and calretinin.
    Takei H; Buckleair LW; Rivera A; Powell SZ
    Pathol Int; 2007 Dec; 57(12):775-83. PubMed ID: 17988278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease.
    Park JY; Paik SR; Jou I; Park SM
    Glia; 2008 Aug; 56(11):1215-23. PubMed ID: 18449945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
    Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
    Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule oxidation products trigger disease-associated protein misfolding.
    Bieschke J; Zhang Q; Bosco DA; Lerner RA; Powers ET; Wentworth P; Kelly JW
    Acc Chem Res; 2006 Sep; 39(9):611-9. PubMed ID: 16981677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the amino acid sequence motif of alpha-synuclein responsible for macrophage activation.
    Lee SB; Park SM; Ahn KJ; Chung KC; Paik SR; Kim J
    Biochem Biophys Res Commun; 2009 Mar; 381(1):39-43. PubMed ID: 19351591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metal-dependent generation of reactive oxygen species from amyloid proteins implicated in neurodegenerative disease.
    Allsop D; Mayes J; Moore S; Masad A; Tabner BJ
    Biochem Soc Trans; 2008 Dec; 36(Pt 6):1293-8. PubMed ID: 19021543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans.
    Kuwahara T; Koyama A; Koyama S; Yoshina S; Ren CH; Kato T; Mitani S; Iwatsubo T
    Hum Mol Genet; 2008 Oct; 17(19):2997-3009. PubMed ID: 18617532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation.
    Takahashi T; Mihara H
    Acc Chem Res; 2008 Oct; 41(10):1309-18. PubMed ID: 18937396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.